We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




MicroRNA Panel Detects Concussion Symptoms in Children

By LabMedica International staff writers
Posted on 27 Nov 2017
A panel of microRNAs has been shown to be a potent biomarker for the detection of prolonged concussion symptoms in children.

MicroRNAs (miRNAs) are a family of noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are transported through the extracellular space protected in exosomes and microvesicles, which allows them to be easily measured in biofluids, including serum, cerebrospinal fluid, and saliva. Because of their abundance, stability in fluctuating pH levels, resistance to enzymatic degradation, and essential role in transcriptional regulation, miRNAs make ideal biomarkers.

Approximately one-third of children who suffer a concussion develop prolonged concussion symptoms. These include headache, nausea, confusion, amnesia, or lack of consciousness. While most concussions disappear within two weeks, some patients will experience symptoms longer. There are currently no objective or easily administered tests for predicting prolonged concussion symptoms, and although several studies have identified alterations in miRNAs following traumatic brain injury, no studies have examined whether miRNA expression can detect prolonged concussion symptoms.

Investigators at Pennsylvania State University College of Medicine (Hershey, USA) recently published results of a study that was designed to fill this gap.

They conducted a prospective study comprising the observation of 52 patients aged seven to 21 years who had presented for evaluation of concussion within 14 days of initial head injury, with follow-up at four and eight weeks. Each participant was evaluated using the Sport Concussion Assessment Tool (SCAT-3), a common tool used to inventory concussion symptoms and severity. Salivary miRNA expression was measured at the time of initial clinical presentation in all patients.

Results revealed that levels of five miRNAs (miR-320c-1, miR-133a-5p, miR-769-5p, let-7a-3p, and miR-1307-3p) accurately identified patients with prolonged symptoms. Levels of three miRNAs were associated with specific symptoms four weeks after injury. MiR-320c-1 was associated with memory difficulty, miR-629 was associated with headaches, and let-7b-5p was associated with fatigue.

"The microRNAs were able to predict whether symptoms would last beyond four weeks with about 85% percent accuracy," said senior author Dr. Steven Hicks, assistant professor of pediatrics at Pennsylvania State University College of Medicine. "In comparison, using the SCAT-3 report of symptoms alone is about 64% accurate. If you just go off the parent's report of symptoms, it goes down to the mid-50s. In this pilot study, these molecular signatures are outperforming survey tools. The ultimate goal is to be able to objectively identify that a concussion has happened and then predict how long the symptoms will go on for. Then we can use that knowledge to improve the care that we provide for children who have concussions, either by starting medicine earlier or holding them out of activities for longer."

Related Links:
Pennsylvania State University College of Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.